This analysis evaluates-from a US payer's perspective-the economic impact of using rivaroxaban versus enoxaparin for thromboprophylaxis following total hip or knee replacement surgery.
Brahim K. Bookhart, MBA, MPH
Advertisement
Articles by Brahim K. Bookhart, MBA, MPH
Advertisement
Latest Updated Articles
- Economic Model Comparing Rivaroxaban and Enoxaparin for Post-Orthopedic VTE Prophylaxis
Published: June 6th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Combination of Olezarsen and Fibrates Yields Enhanced Triglyceride Reduction
2
Essential Oils: A Pharmacist Guide for Alternative Pain Management
3
Technological Developments Usher in the Future of Medication Safety
4
Pharmacy and Medically Underserved Areas Enhancement Act Offers New Hope
5
